Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 10thth October 2019 8:15am – 9:30am
Venue	Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Ms J Morgan, Professional Secretary, Senior Principal Pharmacist - Formulary Prof M Lind, Vice Chair, Professor of Oncology Dr S Raise, GP ER CCG (via phone link) Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr K McCorry, Medicines Optimisation Pharmacist, NECS (via phone link) Dr F Umerah, Consultant Anaesthetist Dr B Ali, GP Hull CCG Mr S P Gaines, Deputy Chief Pharmacist, Lead Pharmacist Medicine Safety Mr P O'Brien, Deputy Chief Pharmacist Dr H Klonin, Consultant Paediatrician
Apologies	Dr A Samson, Infectious Diseases Consultant Dr O Ogunbambi, Consultant Rheumatologist

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2019.10.01	**Apologies**	As above					10/19
2019.10.02	**Declarations of Interest**	None					10/19
2019.10.03	**Minutes of the previous meeting**	Amend p6. Pentosan “when further advice was forthcoming” Accepted as a true record with amendment					10/19
2019.10.04	**Action Tracker**	**Tracker** Methotrexate was discussed at HERPC	Action complete	No further action	WH		
		Tracker Unlicensed meds to be added to November agenda – ongoing	Ongoing	Agenda for November	WH		
		New Product Request AM has written to applicants and WH has updated formulary	Action complete	No further action	AM/WH		
		New Product Request JM has discussed Cavilon Advance with tissue viability team regarding plans for use. Tissue viability team will initially provide first two doses (1 weeks supply) and then review the patient.	Approved WH to add to formulary and AM to write to applicant		AM/WH		
		NICE Guidance TA592 Cemiplimab has been added to back of formulary	Action complete	WH to chase ARIA form	WH		
		NICE Guidance TA595 Dacomitinib WH has added to back of formulary. ML said that oncology have not decided if they will be going forward with this so an ARIA form may not be required.	Action complete	No further action	WH		
		NICE Guidance TA 596 Risankizumab. POB informed the committee that there was work being done over the next 3 months on a document show which MABs were clinically appropriate and cost effective for different dermatological conditions	Action complete	No further action	POB		

		New Product Request Form AR has discussed amendments with JM and the amendments have been made **Review of Use of Aprotinin** WH has added to March 2020 agenda. POB mentioned that unfortunately HUTH were not yet fully compliant with this procedure 4 patients had been given Aprotinin but had not been recorded. Cardiology pharmacist to request Prof Loubani raise at next governance meeting as this protocol must be adhered to. **AOB** SR has sent AR details of ADHD patients. **AOB** Freestyle Libre was discussed at HERPC **AOB** KMc has not yet emailed GPs regarding Pentosan as awaiting final decision from HERPC	Action complete POB to email Dr Hibbert Action complete Action complete Action complete	No further action No further action	JM/AR POB SR WH KMc		
2019.10.05	**New Product Requests**	Tafamidis –Cardiac Transthyretin Amyloidosis - Prof A Clark Available via EAMS scheme and once licensed NHSE via Blueteq. Product launch expected in 2020. If approved product will be high cost NHSE drug. Evidence presented consisted of 1 trial made up of 441 patients Bictegravir/Emtricitabine/Tenofovir – HIV – K o'Keeffe Dibotermin alfa/rhBMP-2 - single level interbody fusion through an anterior or lateral approach to the spine - Mr V Arzoglou Requested by spinal surgeons and NHSE commissioned for this indication. Product is also licensed for tibial fractures but not NHSE commissioned for this indication	Approved for use by Prof Clark Only Approved Approved JM to discuss with orthopaedics to find out if they wish to make a separate submission	AM to write to applicants and WH to update formulary JM to speak to orthopaedics	AM/WH JM		
2019.10.06	**NICE Guidance – Sept 19**	TA565 Benralizumab for treating severe eosinophilic asthma (Update) TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia – NPR was rejected for this in Dec 18 however now product has	Noted AM to write to Prof Bhandari		AM	11/19	

		NICE TA committee agreed to approve	with decision				
		TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	All drugs on formulary				
		TA601 Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)	Noted				
		TA602 Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	Noted				
		TA603 Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)	Noted				
		NG33 Tuberculosis	All drugs on formulary				
		NG137 Twin and triplet pregnancy	All drugs on formulary				
		NG138 Pneumonia (community-acquired): antimicrobial prescribing NG139 Pneumonia (hospital-acquired): antimicrobial prescribing	All drugs on formulary. JM to check documents have gone to ACAT		JM	11/19	
		NG140 Abortion care	All drugs on formulary				
		NG141 Cellulitis and erysipelas: antimicrobial prescribing	All drugs on formulary. JM to check documents have gone to ACAT		JM	11/19	
		NG87 Attention deficit hyperactivity disorder: diagnosis and management	All drugs on formulary				

		CG191 Pneumonia in adults: diagnosis and management CG176 Head injury: assessment and early management CG132 Caesarean section	All drugs on formulary All drugs on formulary All drugs on formulary				
2019.10.07	**MHRA Drug Safety Update**	September 19 HRT: further information on the known increased risk of breast cancer with HRT and its persistence after stopping Fingolimod: Increased risk of congenital malformations Elmiron: Rare risk of pigmentary maculopathy Monteleukast : Reminder of the risk of neuropsychiatric reactions	Noted	No further action			10/19
2019.10.10	**Minutes from HERPC**	July 19	Noted				10/19
2019.10.11	**Minutes from SMPC**	July 19 DC informed the committee SMPC where currently reviewing all old NPSA alerts to ensure compliance and had discussed a recent event involving midazolam. SG said that in June 2019 D&T had rejected an application for Ozalin a licensed oral midazolam product due to its container and the possibility of it being mistaken for an injectable product this decision was confirmed by SMPC but now there was another oral liquid midazolam product available in an amber bottle which was unlicensed. It was agreed that if a request was made to stock this product it would need to be risk assessed and a NPR form should be completed to demonstrate which cohort of patients it would be used in and for which indications.	Noted				10/19
2019.10.12	**Regional Medicines Optimisation Committees**	None this month					10/19

2019.10.13	**Correspondence received**	None this month					10/19
2019.10.14	**Chairs approvals**	Moxidectin - recurrent, recalcitrant biopsy confirmed scabies – Dr P Lilley. POB said currently HUTH where having trouble sourcing a appropriate product which was licensed for human use	Noted				10/19
2019.10 15	**Issues to escalate to OQC**	None this month					10/19
2019.10.16	**Any Other Business**	HK asked if anyone had been involved in preparing for BREXIT. DC said BREXIT was included as part of the winter pressure planning meetings that took place every Tuesday. POB also explained that systems had already begun being implemented in community such as serious shortage protocols POB raised the issue of Ranitidine withdrawal. GSK have withdrawn all Zantac products from the market due to concerns over the breakdown product NDMA. Zantac is the only brand of ranitidine injection available. HUTH are currently reviewing where all ranitidine products are used and looking at possible alternatives if all ranitidine products have to be withdrawn. MHRA are currently reviewing the situation and have asked wholesalers to quarantine all brands. KMc said currently in Hull there were 170 patients and in ER there were 170 patients receiving ranitidine. WH said that Dr Lilley wished to use Cidofovir for a patient and was going to submit a chairs approval but upon investigation Cidofovir had been approved in 2009. Committee agreed to add to formulary and that there was no requirement for chairs approval submission.	Noted WH to add Cidofovir to formulary				10/19
2019.10.17	**Date and Time of Next Meeting**	**Date:** Thursday 14th November 2019 **Time:** 8.15-9.30am **Venue:** Pathology Meeting Room. Pathology Building, HRI					